The study of aspirin resistance in patients with coronary heart disease by flow cytometry

( views:155, downloads:0 )
Author:
WEI Jian-rui(Department of Cardiology,The Fourth Affiliated Hospital of Ji'nan University,Guangzhou Red Cross Hospital,Guangzhou,Cruangdong 510220,China[Abstract]Objective To observe the effect of aspirin on phtelets activation markers in patients with coronary heart)
WU Ying-ying(Department of Cardiology,The Fourth Affiliated Hospital of Ji'nan University,Guangzhou Red Cross Hospital,Guangzhou,Cruangdong 510220,China[Abstract]Objective To observe the effect of aspirin on phtelets activation markers in patients with coronary heart)
ZHANG Wen-chao(Department of Cardiology,The Fourth Affiliated Hospital of Ji'nan University,Guangzhou Red Cross Hospital,Guangzhou,Cruangdong 510220,China[Abstract]Objective To observe the effect of aspirin on phtelets activation markers in patients with coronary heart)
GUO Zhuang-bo(Department of Cardiology,The Fourth Affiliated Hospital of Ji'nan University,Guangzhou Red Cross Hospital,Guangzhou,Cruangdong 510220,China[Abstract]Objective To observe the effect of aspirin on phtelets activation markers in patients with coronary heart)
JIANG Zuo-feng(Department of Cardiology,The Fourth Affiliated Hospital of Ji'nan University,Guangzhou Red Cross Hospital,Guangzhou,Cruangdong 510220,China[Abstract]Objective To observe the effect of aspirin on phtelets activation markers in patients with coronary heart)
ZHANG Rui(Department of Cardiology,The Fourth Affiliated Hospital of Ji'nan University,Guangzhou Red Cross Hospital,Guangzhou,Cruangdong 510220,China[Abstract]Objective To observe the effect of aspirin on phtelets activation markers in patients with coronary heart)
Journal Title:
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
Issue:
Volume 15, Issue 08, 2008
DOI:
Key Word:
Coronary disease;Aspirin resistance;Flow cytometry

Abstract: Objective To observe the effect of aspirin on phtelets activation markers in patients with coronary heart disease and set up a diagnostic criteria of aspirin resistance.To preliminarily predict the incidence of aspirin resistance in hospital patients.Methods The subjects were divided into 3 groups:aspirin group(103 cases),control group(24 eases),and healthy control group(23 cases).Using whole blood samples,we detected the ratio of CD62P,PAC-1 expression by flow cytometry(FCM)before and after 7-day treatment and compared the changes of CD62P and PAC-1 expression ratio,then calculated the inhibition ratio of platelets glycoprotein,set up the diagnostic criteria of aspirin resistance with receiver operator characteristic curve(SOC)and calculate the incidenee of aspirin resistance in hospital patients.Results The statisticsl reaults are listed as below:in asptirin group,before treatment CD62P(10.16±6.80)%,PAC-1(14.66±10.56)%,and after treatment CD62P(5.70±4.28)%,PAC-1(8.93±7.08)%,P<0.01.In control group,before treatment CD62P(9.14±6.52)%,PAC-1(17.67±11.53)%,and after treatment CD62P(7.81±5.72)%,PAG-1(14.97±8.05)%,P<0.05.According to ROC,the inhibition ratio of CD62P<21.5% or PAG-1<17.7% was individually set up asdiagnostic criteria of AR.Our study indicate that the incidence of aspirin resistance in hospital CHD patients is 17.5%.Conclusion There exists platelet activation in CHD patients.CD62P and PAC-1 could be considered as the sensitive index of platelet activation and used in the evaluation of anti-platelet therapy.Aspirin can decrease the expression of CD62P and PAC-1,and inhibit the activation of platelet.According to this study,aspirin resistance really exists in CHD patients.By FCM,the diagnostic criteria of aspirin resistance in CHD is the inhibition ratio of CD62P<21.5% or PAC-1 <17,7% due to aspirin.The incidence of aspirin resistance in hospital CHD patients is 17.5%.

  • [1]Riker PM,Cook NR,Lee IM,et al.A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.N Eng J Med,2005,352(13):1293-1304.
  • [2]Patrono C,Coller B,FitzGerald GA,et al.Platelet-active drugs:the relationships among dose,effectiveness,and side effects the seventh ACCP conferance on antithrombotic and thrombolytic therapy.Chest,2004,126(3 Suppl):234S-264S.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn